► Subscribe to Newsletter

Subscribe to Newsletter

Please enter your name and email address if you would like to subscribe to the monthly Thrombosis Adviser Newsletter.

First Name *
Last Name *
Email *

I confirm that I am a Health Care Professional (HCP) and that I have read and accepted the Privacy Statement and the Conditions of Use.

* Required Fields

Please enter your first name.

Please enter your last name.

Please enter correct email address.

Please confirm that you are a Health Care Professional (HCP).

References

1 Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345(11):779-783.

2 Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol. 2008;28(3):367-369.

3 Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):381S-453S.

4 Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370(9587):604-618.

5 Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937-954.

6 Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ. Overview of hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:3-16.

7 Tran H, Ginsberg J. Anticoagulant therapy for major arterial and venous thromboembolism. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1673-1688.

8 Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):1037-1052.

9 Miller KL, Pollack CV Jr, Peterson ED. Moving from evidence to practice in the care of patients who have acute coronary syndrome. Cardiol Clin. 2006;24(1):87-102.

10 Adams GL, Manson RJ, Turner I, Sindram D, Lawson JH. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am. 2007;21(1):13-24.

11 Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617.

12 Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-764.

13 Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23(1):17-25.

14 Colman RW, Marder VJJ, Clowes AW. Overview of coagulation, fibrinolysis and their regulation. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. iHemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:17-20.

15 Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007;21(1):1-11.

16 Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.

17 Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.

18 Waldo AL. Anticoagulation: stroke prevention in patients with atrial fibrillation. Med Clin North Am. 2008;92(1):143-159, xi.

19 Harkess JW, Arthroplasty of hip. In: Canale ST, ed. Campbell’s Operative Orthopedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003. Available at www.mdconsult.com. Accessed February 12, 2008.

20 Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268-277.

21 Fitzmaurice DA, Murray E. Thromboprophylaxis for adults in hospital. BMJ. 2007;334(7602):1017-1018.

22 Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.

23 Bassand JP, Hamm CW, Ardissino D, et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.

24 Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics―2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.

25 Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887-890.

26 Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med. 2006;22(1):75-92, viii-ix.

27 Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005; 26(1):3-4.

28 Lip GY, Blann AD. Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state? J Am Coll Cardiol. 2000;36(7):2044-2046.

29 1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie. Prophylaxe der venösen Thromboembolie (VTE) Version vom 18. März 2009.

30 Alikhan R, Cohen AT, Combe S, et al; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963-968.

31 Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977.

32 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222-1231.

33 Padanilam BJ, Prystowsky EN. Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Med Clin North Am. 2008;92(1):217-235, xii-xiii.

34 Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008 ;92(1):17-40, ix.

35 Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol. 2000;35(7):1926-1931.

36 British Heart Foundation. European Cardiovascular Disease Statistics, 2008. http://www.heartstats.org/datapage.asp?id=7683. Accessed March 8, 2008.

37 National Cholesterol Education Program, Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII). National Cholesterol Education Program. National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 02-5215. September 2002.

38 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-974.

39 Gorelick PB. Epidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiovascular disease. Clin Cardiol. 2004;27(5)(suppl 2), II4-II11.

40 Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.

41 Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost. 2005;3(8):1554-1560.

42 Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part I. Diagnosis. Am Fam Physician. 2004;69(12):2829-2836.

43 Kearon C, Hirsh J. Cardiovascular medicine: XVIII. Venous thromboembolism. In: Dale DC, ed. ACP Medicine. New York, NY: WebMD, Inc; 2007:1-15. http://www.acpmedicine.com/acp_home.htm. Accessed February 12, 2008.

44 Stern JB, Abehsera M, Grenet D, et al. Detection of pelvic vein thrombosis by magnetic resonance angiography in patients with acute pulmonary embolism and normal lower limb compression ultrasonography. Chest. 2002;122(1):115-121.

45 Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795-1798.

46 Saad WE, Saad N. Computer tomography for venous thromboembolic disease. Radiol Clin North Am. 2007;45(3):423-445.

47 The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA. 1990;263(20):2753-2759.

48 Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006;332(7535):215-219.

49 Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol. 1999;34(7):1867-1877.

50 Rastegar R, Harnick DJ, Weidemann P, et al. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol. 2003;41(4):603-610.

51 Anderson JL. ST segment elevation myocardial infarction and complications of myocardial infarction. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007. www.mdconsult.com. Accessed February 12, 2008.

52 Waters DH. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007. www.mdconsult.com. Accessed February 12, 2008.

53 Milner KA, Funk M, Richards S, Wilmes RM, Vaccarino V, Krumholz HM. Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol. 1999;84(4):396-399.

54 Tapson VF, Decousus H, Pini M, et al; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936-945.

55 Kakkar AK. Prevention of venous thromboembolism in general surgery.In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1361-1367.

56 Motte S, Samama CM, Guay J, Barré J, Borg JY, Rosencher N. Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis. Can J Anaesth. 2006;53(6)(suppl):S68-S79.

57 Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.

58 White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.

59 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348(9022):224-228.

60 Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25(2):101-161.

61 Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259-262.

62 Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505.

63 Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363(9417):1295-1305.

64 Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007;356(14):1438-1444.

65 White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I4-I8.

66 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.

67 Cohen AT, Davidson BL, Gallus AS, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325-329.

68 Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800.

69 Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-288.

70 Levine MN, Lee AYY, Kakkar AK. Cancer and Thrombosis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1251-1262.

71 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.

72 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464

73 Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I22-I30.

74 Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis. 2006;21(1):41-48.

75 Haenen JH, Janssen MC, van Langen H, et al. The postthrombotic syndrome in relation to venous hemodynamics, as measured by means of duplex scanning and strain-gauge plethysmography. J Vasc Surg. 1999;29(6):1071-1076.

76 Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.

77 Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.

78 Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345(20):1465-1472.

79 Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):2370-2375.

80 Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.

81 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546-554.

82 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.

83 Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.

84 Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33(4):901-906.

85 Fletcher GF, Bufalino V, Costa F, et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 2007;99(6C):1E-35E.

86 Vesely MR, Kelemen MD. Cardiac risk assessment: matching intensity of therapy to risk. Cardiol Clin. 2006;24(1):67-78.

87 Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056-1061.

88 Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007;16(4):431-440.

89 Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.

90 Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-727.

91 Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1)(suppl):132S-175S.

92 Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453-463.

93 Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1)(suppl):8S-21S.

94 Verstraete M, Prentice CR, Samama M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest. 2000;117(6):1755-1770.

95 Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.

96 Haines S, Racine E, Zeolla M. Venous thromboembolism. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells G, Posey L, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: McGraw-Hill Companies, Inc.; 2002:337-373.

97 Shurin SB, Nabel EG. Pharmacogenomics—ready for prime time? N Engl J Med. 2008;358(10):1061-1063.

98 Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999-1008.

99 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641-1647.

100 Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89(1):432-449.

101 Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, and Weitz JI. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6)(suppl): 141S–159S.

102 Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005;19(1):1-51, v.

103 Wu CL. Regional anesthesia and anticoagulation. J Clin Anesth. 2001;13(1):49-58.

104 Warkentin TE, Greinacher A, Koster A, and Lincoff AM. Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):340S-380S.

105 Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3(8):1843-1853.

106 Frenkel EP, Shen YM, Haley BB. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am. 2005;19(1):119-145, v-vii.

107 Messmore HL Jr, Jeske WP, Wehrmacher W, et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am. 2005;19(1):87-117, vi.

108 Roth GJ. Antiplatelet therapy. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1725-1737.

109 Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2007.

110 Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041-2050.

111 National Collaborating Centre for Acute Care. Venous Thromboembolism: Reducing the Risk for Surgical Inpatients. London, England: Royal College of Surgeons of England; 2007:1-163.

112 Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 2005;9(49). :iii-iv, ix-x, 1-78.

113 Schulz SL, Stechemesser B, Seeberger U, Meyer D, Kesselring C. Graduated compression stockings for the prevention of venous thromboembolism in surgical patients in the age of low molecular weight heparins. J Thromb Haemost. 2005;3(10):2363-2365.

114 Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br. 2007;89(7):887-892.

115 Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation.2004;110(24)(suppl 1):IV4-IV12.

116 Wilson NV, Das SK, Kakkar VV, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg Br. 1992;74(1):50-52.

117 Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002;84(3):344-350.

118 Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest.2003;124(6)(suppl):349S-356S.

119 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879.

120 Lee AY, Levine MN, Baker RI, et al;.Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.

121 Kahn SR, Shbaklo H, Shapiro S, et al; SOX Trial Investigators. Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord. 2007;7:21. http://www.biomedcentral.com/1471-2261/7/21. Accessed April 30, 2008.

122 Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998; (7):409-415.

123 Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost. 2006;32(8):838-847.

124 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):454S-545S.

125 Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med.1999;131(9):688-695.

126 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.

127 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.

128 Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-2696.

129 Gelfand EV, Cannon CP. Acute Coronary Syndrome. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1387-1404.

130 Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.

131 Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(suppl 1):60-64.

132 Novel oral anticoagulant Pradaxa (dabigatran etexilate) approved by the European Commission [press release]. http://www.fiercebiotech.com/press-releases/novel-oral-anticoagulant-pradaxa-dabigatran-etexilate-approved-european-commission. Accessed April 10, 2008.

133 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124(3)(suppl):58S-68S.

134 Suo Z, Citron BA, Festoff BW. Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders. Curr Drug Targets Inflamm Allergy. 2004;3(1):105-114.

135 Bates SM, Weitz JI. New antithrombotic drugs. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1763-1783.

136 Rich JD, Wiviott SD. New antiplatelet therapies for acute coronary syndromes. Curr Cardiol Rep. 2007;9(4):303-311.

137 Yoshida S, Sudo T, Niimi M, et al. Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito. Blood. 2008;111(4):2007-2014.

138 Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005;108(2):180-192.

139 Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113(9):1244-1254.

140 Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia, PA: WB Saunders, Co.; 2000.

141 Chung CS, Caplan LR. Neurovascular disorders. In: Goetz CG, ed. Textbook of Clinical Neurology. 2nd ed. Philadelphia, PA: Elsevier Science; 2003:991-1016.

142 Schoen FJ. Blood vessels. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier, Inc.; 2005. Available at www.mdConsult.com. Accessed March 17, 2008.

143 Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost 2007;5(8):1607-1609.

144 Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. [Abstract 910]. Blood 2005;106(11):267a.

145 House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf

146 Ferri F. Ferri's Clinical Advisor. 2004: Instant diagnosis and treatment. 6th ed. St Louis, MO: Mosby; 2003.

147 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med.1998;158(6):585-593.

148 Kearon C. Natural history of venous thromboembolism. Semin Vasc Med. 2001;1(1):27-37.

149 Sandler DA. Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4): 203-205.

150 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983– 988.

151 Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74(3):236-241.

152 Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet2008;372(9632):31-39.

153 Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU [press release]. Leverkusen, Germany: Bayer HealthCare AG; October 1, 2008; http://www.xarelto.com/html/press/pdf/2008-0442E.pdf . Accessed March 8, 2011.

154 Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program [press release]. PRINCETON, N.J. & NEW YORK: Bristol-Myers Squibb Company & Pfizer Inc.; August 26, 2008; http://www.businesswire.com/news/home/20081211006335/en/Bristol-Myers-Squibb-Pfizer-Provide-Update-Apixaban-Clinical . Accessed March 8, 2011.

155 AAOS [American Academy of Orthopedic Surgeons]. Clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Orthopedic Surgeons Board of Directors; 2007.

156 Ahrens I, Lip GY, Pete K. New oral anticoagulant drugs in cardiovascular disease. Thomb Haemost. 2010;104(1):49-60.

157 Angiomax [package insert]. Parsippany, NJ: The Medicines Company; 2005.

158 Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.

159 ARYx Therapeutics, Inc. Efficacy of tecarfarin mirrors earlier studies while primary endpoint missed. Press release, issued on July 9, 2009. www.medicalnewstoday.com/articles/156856.php. Accessed May 31, 2010.

160 AstraZeneca Pharmaceuticals Inc. European Commission approves Brilique (ticagrelor tablets). http://www.astrazeneca.com/Media/Press-releases/Article/European-Commission-Approves-Brilique. Accessed December 15, 2010.

161 Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):844S-886S.

162 Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010;363(26):2499-2510.

163 Bavry AA, Kumbhani DJ, Rassi, AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials J Am Coll Cardiol. 2006;48(7):1319-1325.

164 Bergmann JF, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010;103(4):736-748.

165 Boehringer Ingelheim. Pradax (gabidatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2010/27_october_2010_dabigatran.html. Accessed March 4, 2011.

166 Boersma E; Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27(7):779-788.

167 Borris LC. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag. 2008;4(4):855-862.

168 Brenner B. State of the art thrombosis prevention and treatment. Therapy. 2008;5(2):123-124.

169 Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.

170 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. 2007;334(7595):674.

171 Committee for Medicinal Products for Human Use (CHMP). Public statement on possible interactions between clopidogrel and proton pump inhibitors. London, England: European Medicines Agency; 2009.

172 Committee for Medicinal Products for Human Use (CHMP). Monthly report, March 2010. London, England: European Medicines Agency; 2010.

173 Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12):1139-1151.

174 Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-1876.

175 Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–2078.

176 Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.

177 Coulter SA. Echocardiographic evaluation of coronary artery disease. In: Willerson JT, Cohn NJ, Wellens HJ, Holmes DR Jr, eds. Cardiovascular Medicine. 3rd ed. London, England: Springer-Verlag London Limited; 2007:811-839.

178 Davizon P, López JA. Microparticles and thrombotic disease. Curr Opin Hematol. 2009;16(5):334-341.

179 Decousus H, Tapson VF, Bergmann JF, et al; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79.

180 Dennis M, Sandercock PA, Reid J, et al; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373(9679):1958-1965.

181 Dougu N, Takashima S, Sasahara E, et al. Differential diagnosis of cerebral infarction using an algorithm combining atrial fibrillation and D-dimer level. Eur J Neurol. 2008;15(3):295-300.

182 Dresang LT, Fontaine P, Leeman L, King VJ. Venous thromboembolism during pregnancy. Am Fam Physician. 2008;77(12):1709-1716.

183 Duke Clinical Research Institute website. ORBIT-A registry 2010. www.dukehealth.org. Accessed May 21, 2010.

184 Effient [package insert]. Indianapolis, IN: Eli Lilly & Company, Inc.; 2010.

185 Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290(8):1071-1074.

186 Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30(3):382-387.

187 Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120(12):1029-1035.

188 Eriksson BI, Dahl OE, Lassen MR, et al; Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6(3):457-463.

189 Eriksson BI, Dahl OE, Rosencher N, et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-2185.

190 Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949-956.

191 Eriksson BI, Turpie AG, Lassen MR, et al. Once daily YM150, an oral direct Factor Xa inhibitor, for prevention of venous thromboembolism in patients undergoing elective primary hip replacement. Abstract of oral session presented at 49th American Society of Hematology Annual Meeting, Atlanta, Georgia, USA, December 8–11, 2007. Blood. 2007;110(11)(Part 1):309.

192 Ezekowitz MD, Reilly PA, Nehimz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419-1426.

193 Fareed J, Wahi R, Hoppensteadt DA. An update on new anticoagulant drugs. East J Med. 2009;14(2):84-93.

194 Friedman RJ. New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis. 2010:1-9. Article ID 280731.

195 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.

196 Gaglia MA Jr, Manoukian SV, Waksman R. Novel antiplatelet therapy. Am Heart J. 2010;160(4):595-604.

197 Galanaud JP, Quenet S, Rivron-Guillot K, et al.; RIETE Investigators. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost. 2009;7(12):2028-2034.

198 Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag. 2010;6:109-112.

199 Goldhaber SZ. Cardiovascular medicine: XVIII. Venous thromboembolism. In: Dale DC, ed. ACP Medicine. New York, NY: WebMD, Inc; 2010:1-15.

200 Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010;8(1):43-53.

201 Haas S. New anticoagulants - towards the development of an "ideal" anticoagulant. Vasa. 2009;38(1):13-29.

202 Haines ST, Mitt DM, Nutescu EA. Venous thromboembolism. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells G, Posey L, eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill Companies Inc; 2008:331-371.

203 Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114(5)(suppl):489S-510S.

204 Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53(18):1642–1650.

205 Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54(2):95-109.

206 Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.

207 Hull, RD, Schellong, SM, Tapson, VF, et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) Study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18.

208 James AH. Pregnancy and thrombotic risk. Crit Care Med. 2010;38(2)(suppl):S57-S63.

209 Kakkar AK, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg. 2010;251(2):330-338.

210 Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40(3):484-490.

211 Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901-907.

212 Kearon C, Ginsberg JS, Anderson DR, et al; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2(5):743-749.

213 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.

214 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.

215 Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.

216 Kluge A, Mueller C, Strunk J, Lange U, Bachmann G. Experience in 207 combined MRI examinations for acute pulmonary embolism and deep vein thrombosis. AJR Am J Roentgenol. 2006;186(6):1686-1696.

217 Kuliczkowski W, Floyd J, Malinin A, Serebruany V. Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Rev Cardiovasc Ther. 2010;8(4):503-507. http://www.medscape.com/viewarticle/722755_print. Accessed December 13, 2010.

218 Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien Klin Wochenschr. 2003;115(13-14):471-474.

219 Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. Curr Opin Cardiol. 2008;23(6):555-559.

220 Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery—TREK: a dose-ranging study. J Thromb Haemost. 2009;7(4):566-572.

221 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 Trial [Abstract OC356]. Presented at the 21st International Congress on Thrombosis, Milan, Italy, July 6-9, 2010. Pathophysiol Haemost Thromb. 2009/2010;37(suppl 1):A20.

222 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.

223 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. New Engl J Med. 2009;361(6):594-604.

224 Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009;66(23):2117-2122.

225 Lee KW, Lip GY. Acute coronary syndromes: Virchow’s triad revisited. Blood Coagul Fibrinolysis. 2003;14(7):605-625.

226 Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484-488.

227 Lip GY, Huber K, Andreotti F, et al; European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the European Society of Cardiology Work Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31(11):1311-1318.

228 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.

229 Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thombogenesis? Clin Sci (Lond). 1995;89(3):205-214.

230 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.

231 Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.

232 Lockie T, Nagel E, Redwood S, Plein S. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Circulation. 2009;119(12):1671-1681.

233 Lyman GH. Venous thromboembolism in the patient with cancer. Focus on burden of disease and benefits of thromboprophylaxis. Cancer. Nov 2010. Epub ahead of print.

234 Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505.

235 Mackman N, Becker RC. DVT: a new era in anticoagulant therapy. Arterioscler Thromb Vasc Biol. 2010;30(3);369-371.

236 Mahaffey KW, Fox KA. Stroke prevention using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [trial slide deck]. Late-breaking clinical trial presented at the 2010 American Heart Association Scientific Session, Chicago, IL, USA, 15 November 2010.

237 Mahé I, Drouet L, Simoneau G, Minh-Muzeaux S, Caulin C, Bergmann JF. D-dimer can predict survival in patients with chronic atrial fibrillation. Blood Coagul Fibrinolysis. 2004;15(5):413-417.

238 Mant J, Hobbs FD, Fletcher K, et al; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503.

239 Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol. 2010:3(2):227–241.

240 Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009;16(5):371-377.

241 Miller GJ, Ireland HA, Cooper JA, et al. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost. 2008;6(2):259-267.

242 Mitsubishi Pharma Europe Ltd. Argatroban Introduction. http://www.argatroban.eu/index2.php?page=24#. Accessed December 10, 2010.

243 Montalescot G, Wiviott SD, Braunwald E, et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised, controlled trial. Lancet. 2009;373(9665):723-731.

244 Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost. 2010;16(2):170-176.

245 National Institute for Health and Clinical Excellence. Final appraisal determination: Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. London, England: National Clinical Guideline Centre; 2009.

246 National Institute for Health and Clinical Effectiveness. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. London, England: National Clinical Guideline Centre – Acute and Chronic Conditions; 2010.

247 Ng TM, Tsai F, Khatri N, Barakat MN, Elkayam U. Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention. Circ Heart Fail. 2010;3(1):165-173.

248 Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol. 2009;29(3):332-336.

249 Paul Coverdell National Acute Stroke Registry. http://www.cdc.gov/dhdsp/programs/stroke_registry.htm. Accessed December 10, 2010.

250 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.

251 Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2010.

252 Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992-1000.

253 Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151-156.

254 RecordAF registry. www.recordaf.org. Accessed May 11, 2010.

255 Refludan [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2007.

256 Ricciardi MJ, Boehar N, Davidson CJ. Cardiac catheterization and coronary angiography. In: Rosendoff C, ed. Essential Cardiology: Principles and Practices. 2nd ed. Totowa, NJ: Humana Press; 2005:197-219.

257 Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55(20):2225-2231.

258 Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol. 2007;17(1):175-181.

259 Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447-451.

260 Scarabin PY, Arveiler D, Amouyel P, et al; Prospective Epidemiological Study of Myocardial Infarction. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis. 2003;166(1):103-109.

261 Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New Engl J Med. 2009;361(24):2342-2352.

262 Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol. 2010;55(14):1403-1415.

263 Summary of product characteristics for Angiox. London, England: European Medicines Agency; 2009.

264 Summary of product characteristics for Arixtra. London, England: European Medicines Agency; 2007.

265 Summary of product characteristics for Effient. London, England: European Medicines Agency; 2010.

266 Summary of product characteristics for Plavix. London, England: European Medicines Agency; 2010.

267 Summary of product characteristics for Pradaxa. London, England: European Medicines Agency; 2008.

268 Summary of product characteristics for Refludan. London, England: European Medicines Agency; 2009.

269 Summary of product characteristics for Xarelto. London, England: European Medicine Agency; 2008.

270 Sweetland S, Green J, Liu B, et al; Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.

271 Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55(8):735-743.

272 Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg. 2008;14(5):274-282.

273 Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997;126(8):638-644.

274 Thrombosis Research Institute website. www.tri-london.ac.uk/research-Garfield.asp. Accessed May 19, 2010.

275 US Food and Drug Administration. Information on clopidogrel bisulphate (marketed as Plavix). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm. Accessed December 15, 2010.

276 van Belle A, Büller HR, Huisman MV, et al; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295(2):172-179.

277 Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003;90(6):1163-1172.

278 Vormittag R, Panzer S, Ay C, Quehenberger P, Koder S, Pabinger I. Soluble P-selectin and thrombosis risk of patients with a persistent lupus anticoagulant in a prospective cohort study [abstract 0878]. Haematologica. 2007;92(suppl 2):327.

279 Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361(11):1045-1057.

280 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658):155-166.

281 Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641.

282 Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998;129(12):997–1005.

283 Wells P, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416–420.

284 Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. IAnn Intern Med. 2001;135(2):98–107.

285 Wijns W, Kolh P, Danchin N, et al; European Association for Percutaneous Cardiovascular Interventions. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31(20):2501-2555.

286 Wilson RF, White CW. Coronary angiography. In: Willerson JT, Cohn JN, Wellens HJJ, Holmes DR Jr, eds. Cardiovascular Medicine. 3rd ed. London, England: Springer-Verlag London Limited; 2007:745-810.

287 Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28(10):973-977.

288 Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298–310.

289 Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008 Jan;92(1):17-40

290 Myasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.

291 Inoue H, Fujiki A, Origasa H, Ogawa S, et al., Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009 Oct 2;137(2):102-7. Epub 2008 Aug 8.

292 Guanella R, Ducruet T, Johri M et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 2011;9:2397–2405.

293 Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e278S–e325S.

294 Turpie AGG, Esmon C. Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011;105:586–596.

295 Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119–125.

296 Lichtlen PR, Nikutta P, Jost S et al. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group. Circulation 1992;86:828–838.

297 Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ 2003;326:1259–1261.

298 Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892–1900.

299 Colman RW, Clowes AW, George JN et al. Overview of coagulation, fibrinolysis and their regulation. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th edn. Colman RW, Clowes AW, George JN et al. (editors). Philadelphia: Lippincott, Williams & Wilkins; 2006. p. 17–20.

300 US Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. Available at: [accessed 21 August 2012].

301 Ruigómez A, Johansson S, Wallander MA, García Rodríguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002;55:358–363.

302 Van de Werf F, Bax J, Betriu A et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2012;33:2569-2619

303 Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:630S–669S.

304 Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463–e654.

305 Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120–138.

306 Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2–e220.

307 Kahn SR, Lim W, Dunn AS et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e195S–e226S.

308 Hull RD, Schellong SM, Tapson VF et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010;153:8–18.

309 Spencer FA, Lessard D, Emery C et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471–1475.

310 Cohen AT, Spiro TE, Büller HR et al. Rivaroxaban for the prevention of venous thromboembolism in acutely ill medical patients: the MAGELLAN study. N Engl J Med 2012.

311 sanofi-aventis US LLC. Lovenox (enoxaparin sodium) Prescribing Information. 2011. Available at: [accessed 21 August 2012].

312 Glaxo Group Ltd. Arixtra (fondaparinux sodium 2.5 mg/0.5 ml injection) Summary of Product Characteristics. 2011. Available at: [accessed 21 August 2012].

313 Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715–1720.

314 Turpie AGG, Bauer KA, Eriksson BI et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721–1726.

315 Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305–1310.

316 Eriksson BI, Bauer KA, Lassen MR et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298–1304.

317 Turpie AGG, Bauer KA, Eriksson BI et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833–1840.

318 Freedman KB, Brookenthal KR, Fitzgerald RH, Jr. et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000;82-A:929–938.

319 Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2012. Available at: [accessed 21 September 2012].

320 Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765–2775.

321 Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776–2786.

322 Turpie AGG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673–1680.

323 Turpie AGG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444–453.

324 Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban) Summary of Product Characteristics. 2011. Available at: [accessed 21 August 2012].

325 Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487–2498.

326 Raskob GE, Gallus AS, Pineo GF et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012;94:257–264.

327 Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2012. Available at: [accessed 21 August 2012].

328 The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1–9.

329 Eriksson BI, Dahl OE, Huo MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721–729.

330 Friedman RJ, Dahl OE, Rosencher N et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thromb Res 2010;126:175–182.

331 Fuji T, Fujita S, Tachibana S et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Blood (ASH Annual Meeting Abstracts) 2010;116:3320.

332 Haines ST, Racine E, Zeolla M. Venous thromboembolism. In Pharmacotherapy: a Pathophysiologic Approach. 5 edn. DiPiro J, Talbert R, Yee G et al. (editors). New York, NY, USA: McGraw-Hill Companies, Inc.; 2002. p. 337–373.

333 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012;141:e24S–e43S.

334 Karthikeyan G, Eikelboom JW, Turpie AGG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009;146:142–149.

335 Kakkar AK, Cimminiello C, Goldhaber SZ et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011;365:2463–2472.

336 Cohen AT, Spiro TE, Büller HR et al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. 2011. Available at:

337 Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012;141:e419S–e494S.

338 Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:340S–380S.

339 Turpie AG, Gent M, Bauer K et al. Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT). J Thromb Haemost 2007;5:Abstract P-T-652.

340 Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I9–I16.

341 Nutescu EA. Antithrombotic therapy for the treatment of venous thromboembolism. Am J Manag Care 2003;9:S103–S114.

342 Malone PC, Agutter PS. The aetiology of deep venous thrombosis. QJM 2006;99:581–593.

343 Blann AD, Lip GYH. Venous thromboembolism. BMJ 2006;332:215–219.

344 Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.

345 Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009;113:2878–2887.

346 Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809–1812.

347 Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769–774.

348 Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199–205.

349 Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–1665.

350 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121:1630–1636.

351 Girard P, Musset D, Parent F et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999;116:903–908.

352 Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276–2315.

353 Lang I. Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br J Haematol 2010;149:478–483.

354 Wells PS, Anderson DR, Rodger M et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000;83:416–420.

355 Poli D, Miniati M. The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. Curr Opin Pulm Med 2011;17:392–397.

356 Douketis JD, Kearon C, Bates S et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458–462.

357 Baglin T, Douketis J, Tosetto A et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis. J Thromb Haemost 2010;8:2436–2442.

358 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657–662.

359 Büller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867–873.

360 The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695–1702.

361 Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006:CD001367.

362 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–2510.

363 The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–1297.

364 Almoosa K. Is thrombolytic therapy effective for pulmonary embolism? Am Fam Physician 2002;65:1097–1102.

365 Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e495S–e530S.

366 Schulman S, Kakkar AK, Schellong SM et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood (ASH Annual Meeting Abstracts) 2011;118. Abstract 205.

367 Schulman S, Ericsson H, Goldhaber SZ et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9 (Suppl. 2):731. Abstract O-TH-033.

368 Schulman S, Baanstra D, Eriksson H et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9 (Suppl. 2):22. Abstract O-MO-037.

369 Kahn SR. How I treat postthrombotic syndrome. Blood 2009;114:4624–4631.

370 Puggioni A, Lurie F. Advances in the surgical treatment of postthrombotic syndrome. Phlebolymphology 2007;14:99–104.

371 Mendoza V, Scharf ML. Evaluation and management of chronic pulmonary thromboembolic disease. Hosp Pract (Minneap ) 2011;39:50–61.

372 Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420.

373 Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534–1539.

374 Heeringa J, van der Kuip DAM, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–953.

375 Lip GYH, Tse HF. Management of atrial fibrillation. Lancet 2007;370:604–618.

376 Jorgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996;27:1765–1769.

377 Thygesen SK, Frost L, Eagle KA, Johnsen SP. Atrial fibrillation in patients with ischemic stroke: A population-based study. Clin Epidemiol 2009;1:55–65.

378 Spieler JF, Lanoe JL, Amarenco P. Socioeconomic aspects of postacute care for patients with brain infarction in France. Cerebrovasc Dis 2002;13:132–141.

379 Fuster V, Ryden LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269–e367.

380 Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263–272.

381 Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012:In press.

382 Olesen JB, Torp-Pedersen C, Hansen ML, Lip GYH. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost 2012;107:1172–1179.

383 You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:531S–575S.

384 Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144–1150.

385 Skanes AC, Healey JS, Cairns JA et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125–136.

386 Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41–57.

387 Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648–661.

388 Alliance Pharmaceuticals. Sinthrome (acenocoumarol) Summary of Product of Characteristics. 2008. Available at:

389 Sandoz Ltd. Warfarin (warfarin sodium 3 mg tablets) Summary of Product of Characteristics. 2010. Available at:

390 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.

391 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.

392 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–817.

393 Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:546S–592S.

394 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860.

395 Apostolakis S, Lane DA, Guo Y et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol 2012;60:861–867.

396 Lip GYH, Banerjee A, Lagrenade I et al. Assessing the risk of bleeding in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Circ Arrhythm Electrophysiol 2012:In press.

397 Verheugt FW. Antithrombotic therapy in heart failure. Neth Heart J 2012;20:176–178.

398 Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;56:1–7.

399 Beemath A, Stein PD, Skaf E et al. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006;98:793–795.

400 Dean SM, Abraham W. Venous thromboembolic disease in congestive heart failure. Congest Heart Fail 2010;16:164–169.

401 Shariff N, Aleem A, Levin V et al. Venous Thromboembolism in Patients with Heart Failure: In-hospital and Chronic Use of Anti-coagulants for Prevention. Recent Pat Cardiovasc Drug Discov 2012;7:53–58.

402 Appelros P. Heart failure and stroke. Stroke 2006;37:1637.

403 Kociol RD, Hammill BG, Hernandez AF et al. Pharmacologic Prophylaxis for Venous Thromboembolism and 30-Day Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis From the ADHERE National Registry Linked to Medicare Claims. Clin Cardiol 2011.

404 Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157–164.

405 Massie BM, Collins JF, Ammon SE et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616–1624.

406 Eikelboom JW, Connolly SJ. Warfarin in heart failure. N Engl J Med 2012.

407 Homma S, Thompson JLP. Warfarin versus aspirin in reduced cardiac ejection fraction trial (WARCEF). International Stroke Conference. New Orleans, LA, USA, 1–3 February 2012; Oral presentation. Available at:

408 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.

409 Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977–2016.

410 Lindenfeld J, Albert NM, Boehmer JP et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e1–194.

411 National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. 2010. Available at:

412 Rodrigues CA, Ferrarotto R, Kalil FR et al. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010;30:67–78.

413 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334–1349.

414 Hurwitz HI, Saltz LB, Van Cutsem E et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:1757–1764.

415 Garcia D, Quintana D. Thrombosis and malignancy: a case-based review. Semin Hematol 2011;48:259–263.

416 Louzada ML, Majeed H, Dao V, Wells PS. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 2011;22:86–91.

417 Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010;125 Suppl 2:S1–S7.

418 Haas S, Schellong SM, Tebbe U et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer 2011;11:316.

419 Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e227S–e277S.

420 Agnelli G, George DJ, Kakkar AK et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–609.

421 Barni S, Labianca R, Agnelli G et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011;9:179.

422 Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007;12:1361–1370.

423 Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–980.

424 Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010;8:1223–1229.

425 Kalka C, Spirk D, Siebenrock KA et al. Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL). Thromb Haemost 2009;102:56–61.

426 Coleman R, Maccallum P. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer 2010;102 Suppl 1:S17–S23.

427 Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2009;20 Suppl 4:182–184.

428 Mandala M, Falanga A, Piccioli A et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006;59:194–204.

429 Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–3083.

430 Trujillo-Santos J, Nieto JA, Tiberio G et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:435–439.

431 Debourdeau P, Beckers M, Gerome P et al. How to improve the implementation of guidelines on cancer-related thrombosis. Expert Rev Anticancer Ther 2011;11:473–483.

432 Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–3488.

433 Debourdeau P, Kassab CD, Le Gal G et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009;20:1459–1471.

434 Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011;31:407–416.

435 Levine MN, Gu C, Liebman HA et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10:807–814.

436 European Heart Network. European cardiovascular disease statistics: 2008 edition. 2008. Available at:

437 US National Center for Health Statistics. National Vital Statistics Reports. Deaths: preliminary data for 2010. 2012. Available at:

438 Overbaugh KJ. Acute coronary syndrome. Am J Nurs 2009;109:42–52.

439 Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 2011 Update: a report from the American Heart Association. Circulation 2011;123:e18–e209.

440 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–1695.

441 Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054.

442 Ault KA, Cannon CP, Mitchell J et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999;33:634–639.

443 Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61–68.

444 Pearte CA, Furberg CD, O'Meara ES et al. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. Circulation 2006;113:2177–2185.

445 Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988;296:320–331.

446 Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81–106.

447 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

448 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

449 Steinhubl SR, Berger PB, Mann JT, III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–2420.

450 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.

451 Myocardial Ischaemia National Audit Project [MINAP]. How the NHS cares for patients with heart attack. Tenth Public Report 2011. London: NICOR: National Institute for Cardiovascular Outcomes Research, University College London; 2011. Available at:

452 Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010;31:2755–2764.

453 Eagle KA, Lim MJ, Dabbous OH et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727–2733.

454 Granger CB, Goldberg RJ, Dabbous O et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345–2353.

455 Braunwald E, Angiolillo D, Bates E et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol 2008;31:I17–I20.

456 Kushner FG, Hand M, Smith SC, Jr. et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271–2306.

457 Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e426–e579.

458 Antman EM, Hand M, Armstrong PW et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117:296–329.

459 Kushner FG, Hand M, Smith SC, Jr. et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205–2241.

460 Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012;141:e637S–e668S.

461 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

462 Roe MT, Armstrong PW, Fox KA et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012:In press.

463 Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19.

464 Dewilde S, Valgimigli M. WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI). 2012. Available at:

465 Ducrocq G, Wallace JS, Baron G et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010;31:1257–1265.

466 Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669–677.

467 Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J Renin Angiotensin Aldosterone Syst 2005;6:43–48.

468 Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.

469 Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–952.

470 Heit JA, Kobbervig CE, James AH et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697–706.

471 Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996;335:108–114.

472 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311–1315.

473 Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. J Pregnancy 2011;2011:206858.

474 Kruithof EK, Tran-Thang C, Gudinchet A et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987;69:460–466.

475 Krafft A. The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy. Thromb Haemost 2007;98:1155–1156.

476 O'Connor DJ, Scher LA, Gargiulo NJ, III et al. Incidence and characteristics of venous thromboembolic disease during pregnancy and the postnatal period: a contemporary series. Ann Vasc Surg 2011;25:9–14.

477 James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009;29:326–331.

478 White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost 2008;100:246–252.

479 De S, V, Martinelli I, Rossi E et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006;135:386–391.

480 Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002;100:3470–3478.

481 Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e691S–e736S.

482 Dilley A, Austin H, El Jamil M et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000;183:1271–1277.

483 Bauersachs RM, Dudenhausen J, Faridi A et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007;98:1237–1245.

484 Greer IA. Anticoagulants in pregnancy. J Thromb Thrombolysis 2006;21:57–65.

485 Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 2012;163:154–159.

486 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401–407.

487 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334–1349.

488 Bergmann JF, Cohen AT, Tapson VF et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost 2010;103:736–748.

489 Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011;31:407–416.

490 Eagle KA, Goodman SG, Avezum Á et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373–377.

491 Goldberg RJ, Currie K, White K et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2004;93:288–293.

492 Mehta RH, Dabbous OH, Granger CB et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003;92:1031–1036.

493 Hasdai D, Behar S, Wallentin L et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190–1201.

494 Mandelzweig L, Battler A, Boyko V et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27:2285–2293.

495 Schiele F, Bueno H, Hochadel M et al. Gender disparities in the management and in-hospital outcomes acute myocardial infarction: temporal changes between 2006 and 2008. Insights from the Euro Heart Survey ACS III registry. American Heart Association Scientific Sessions 2011. Orlando, FL, USA, 12–16 November 2011; Abstract 12712.

496 Schiele F, Bueno H, Hochadel M et al. Performance measures in ST segment elevation myocardial infarction: 2 years temporal changes and room for improvement. Insights from The Euro Heart Survey ACS III Registry. American College of Cardiology 2011 60th Annual Scientific Session. New Orleans, LA, USA, 2–5 April 2011; Abstract 1072-310.

497 Papp A, Bueno H, Gierlotka M et al. Value of Killip classification first described in 1967 for risk stratification of STEMI and NSTE-ACS in the new millennium: lessons from The Euro Heart Survey ACS Registry. American College of Cardiology 2011 60th Annual Scientific Session. New Orleans, LA, USA, 2–5 April 2011; Abstract E1062.

498 Papp A, Wojakowski W, Gierlotka M et al. Determinants of stroke and its impact on outcome of ACS in clinical practice in Europe: lessons from the Euro Heart Survey ACS Registry. American College of Cardiology 2011 60th Annual Scientific Session. New Orleans, LA, USA, 2–5 April 2011; eAbstract E1139-315.

499 Gitt A, Hochadel M, Wojakowski W et al. Improvement of early invasive treatment for NSTE-ACS over time in clinical practice in Europe: lessons from The Euro Heart Survey ACS Registry. American College of Cardiology 2011 60th Annual Scientific Session. New Orleans, LA, USA, 2–5 April 2011; Abstract 1104-328.

500 Alexander KP, Wang TY, Li S et al. Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. Circ Cardiovasc Qual Outcomes 2011;4:129–135.

501 Forman DE, Chen AY, Wiviott SD et al. Comparison of outcomes in patients aged <75, 75 to 84, and >=85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG). Am J Cardiol 2010;106:1382–1388.

502 Diercks DB, Owen KP, Kontos MC et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J 2010;160:80–87.

503 Guzman LA, Li S, Wang TY et al. Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry-GWTG. J Am Coll Cardiol 2012;59:630–631.

504 Kadakia MB, Desai NR, Alexander KP et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry - GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry - get with the guidelines). JACC Cardiovasc Interv 2010;3:1166–1177.

505 Mathews R, Peterson ED, Chen AY et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry(R)-GWTG. Am J Cardiol 2011;107:1136–1143.

506 Chin CT, Chen AY, Wang TY et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J 2011;161:113–122.

507 Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163:13–19.

508 Camm AJ, Breithardt G, Crijns H et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011;58:493–501.

509 Piccini JP, Fraulo ES, Ansell JE et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart Jv 2011;162:606–612.

510 Use of a registry to improve acute stroke care – seven states, 2005–2009. MMWR Morb Mortal Wkly Rep 2011;60:206–210.

511 Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther 2012;10:283–291.

512 Kirchhof P, Nabauer M, Gerth A et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105:1010–1023.

513 Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423–434.

514 Anderson FA, Jr. Overview of the GLOBAL Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ) 2010;39:2–4.

515 Decousus H, Tapson VF, Bergmann JF et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139:69–79.

516 Spyropoulos AC, Anderson FA, Jr., Fitzgerald G et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011;140:706–714.

517 National Institute for Health and Clinical Excellence. Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation document. 2012. Available at:

518 Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163–1174.

519 Eichinger S, Weltermann A, Minar E et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004;164:92–96.

520 Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. Chest 2012:10.1378/chest.12-0608.

521 Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.

522 Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001;102:295-309.

523 Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2012:699-708.